Literature DB >> 9472654

Immune activation in the context of HIV infection.

Z Bentwich, A Kalinkovich, Z Weisman, Z Grossman.   

Abstract

Entities:  

Mesh：

Year:  1998        PMID： 9472654      PMCID： PMC1904872          DOI： 10.1046/j.1365-2249.1998.00483.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  26 in total

1.  Adaptive cellular interactions in the immune system: the tunable activation threshold and the significance of subthreshold responses.

Authors:  Z Grossman; W E Paul
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

2.  Long-term cultures of HTLV-III--infected T cells: a model of cytopathology of T-cell depletion in AIDS.

Authors:  D Zagury; J Bernard; R Leonard; R Cheynier; M Feldman; P S Sarin; R C Gallo
Journal:  Science       Date:  1986-02-21       Impact factor: 47.728

Review 3.  AIDS as immune system activation. II. The panergic imnesia hypothesis.

Authors:  M S Ascher; H W Sheppard
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

4.  Health profile of Ethiopian immigrants in Israel: an overview.

Authors:  J Nahmias; Z Greenberg; S A Berger; L Hornstein; B Bilgury; B Abel; S Kutner
Journal:  Isr J Med Sci       Date:  1993 Jun-Jul

5.  "Infectious" transplantation tolerance.

Authors:  S Qin; S P Cobbold; H Pope; J Elliott; D Kioussis; J Davies; H Waldmann
Journal:  Science       Date:  1993-02-12       Impact factor: 47.728

6.  Superantigen activation of CD4+ and CD8+T cells from HIV-infected subjects: role of costimulatory molecules and antigen-presenting cells (APC)

Authors:  J Vingerhoets; M Dohlsten; G Penne; R Colebunders; D Sansom; E Bosmans; L Kestens; G Vanham
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

7.  Three-color cytofluorometric analysis of CD8 cell subsets in HIV-1 infection.

Authors:  H E Prince; E R Jensen
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

8.  AIDS as immune system activation: a model for pathogenesis.

Authors:  M S Ascher; H W Sheppard
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

9.  Subset markers of CD8(+) cells and their relation to enhanced cytotoxic T-cell activity during human immunodeficiency virus infection.

Authors:  G Vanham; L Kestens; G Penne; C Goilav; P Gigase; R Colebunders; M Vandenbruaene; J Goeman; G van der Groen; J L Ceuppens
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

Review 10.  Natural resistance to parental T-lymphocyte-induced immunosuppression in F1 hybrid mice: implications for acquired immune deficiency syndrome (AIDS).

Authors:  G M Shearer
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988
View more
  35 in total

Review 1.  Host background immunity and human immunodeficiency virus protective vaccines, a major consideration for vaccine efficacy in Africa and in developing countries.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

2.  Early reduction of the over-expression of CD40L, OX40 and Fas on T cells in HIV-1 infection during triple anti-retroviral therapy: possible implications for lymphocyte traffic and functional recovery.

Authors:  A E Sousa; A F Chaves; M Doroana; F Antunes; R M Victorino
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

3.  Characteristics and outcomes of aplastic anemia in HIV patients: a brief report from the severe aplastic anemia working party of the European Society of Blood and Bone Marrow Transplantation.

Authors:  S Pagliuca; L Gérard; A Kulasekararaj; M Eapen; D Boutboul; H Martin; M A Salvino; C Knol-Bout; C Dufour; R Peffault de Latour; J Marsh
Journal:  Bone Marrow Transplant       Date:  2015-10-19       Impact factor: 5.483

4.  Distinct transcriptional profiles in ex vivo CD4+ and CD8+ T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD8+ T cells.

Authors:  Martin D Hyrcza; Colin Kovacs; Mona Loutfy; Roberta Halpenny; Lawrence Heisler; Stuart Yang; Olivia Wilkins; Mario Ostrowski; Sandy D Der
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

Review 5.  Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  Parasitic disease screening among HIV patients from endemic countries in a Toronto clinic.

Authors:  Cecilia T Costiniuk; Curtis L Cooper; Steve Doucette; Colin M Kovacs
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

7.  Co-infection by human immunodeficiency virus type 1 (HIV-1) and human T cell leukemia virus type 1 (HTLV-1): does immune activation lead to a faster progression to AIDS?

Authors:  Eduardo Samo Gudo; Nilesh B Bhatt; Dulce Ramalho Bila; Celina Monteiro Abreu; Amílcar Tanuri; Wilson Savino; Suse Dayse Silva-Barbosa; Ilesh V Jani
Journal:  BMC Infect Dis       Date:  2009-12-22       Impact factor: 3.090

8.  Quantifying T lymphocyte turnover.

Authors:  Rob J De Boer; Alan S Perelson
Journal:  J Theor Biol       Date:  2013-01-09       Impact factor: 2.691

9.  Decreased CD4 and increased CD8 counts with T cell activation is associated with chronic helminth infection.

Authors:  A Kalinkovich; Z Weisman; Z Greenberg; J Nahmias; S Eitan; M Stein; Z Bentwich
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

10.  T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis.

Authors:  Jason M Brenchley; Brenna J Hill; David R Ambrozak; David A Price; Francisco J Guenaga; Joseph P Casazza; Janaki Kuruppu; Javaidia Yazdani; Stephen A Migueles; Mark Connors; Mario Roederer; Daniel C Douek; Richard A Koup
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.